99 TCOG 99.09.03

*

*

*-1 ()

*-2 1. 2.

*-3() 1. 2. 3. 4.

*

*

*99

*

*

*

*

1.2.1.2

*

1.2() 1234

*

*

*

*

1.2 1. 2. 3. PDCA4.

*

1.3() Rating ERating DRating CRating C

*

*

1.31. (1) (2)2.3.4.

*

*

* 99

*

*

*

*

*

*

*

*

*

2.2.2Rating ERating DRating D80%85%Rating C85%90%Rating B90%95%Rating A95%

*

*

*

*

2.3 1.2.guidelineSOP 3.

*

*

2.41.2.3.4.

*

CB

*

2.5()(Class1~2) Rating E Rating DRating C Rating C1. 2.80

*

*

2.51.() 2.( ))3.10(Class1~2) Stage 4.5.

*

*

CB

*

*

1. 2.

99

1. 2. 3. 4.

3.21. regimenR/T dose 2.comorbidity risk factor3.4. 5.

100

1.2.

100

100

100

CRPRORprogressive

100

1.2.

3.4 1. 2. /

3.51. 2. 3.

3.6.11. 2. 3. AdjuvantNeoadjuvant chemotherapy regimen4. 5. neoadjuvantadjuvant6.

*

3.6.3 Rating ERating DRating CRating C 1. 2.Rating BC Rating AB

*

3.6.31.2. (1. 2.3. 4. )3.(

*

*

3.6.3

4.5.1

Class IIBClass III ()

*

3.6.3

2spill kits

N95 )

3.6.3 near miss

*

3.6.4 Rating ERating DRating CRating C 2 Rating BC Rating A

*

3.6.41.2.3. 1. (1) (2) (3) (4)

*

100

3.6.4

1. 1002.

1. 2.

2.

3.9 1. 2. 3.

* 99

*

*

*

4.1Rating B 3() Rating A 4()

*

*

4.11. 2. 3.

*

*

4.2CCRT

*

*

*

4.3 1.()2.()3.

*

4.3 SOP

*

*

*

*

*

4.435

*

*

*

4.5

*

*

*

*

*

4.6

* 99

*

*

5.1Risk factorIC

*

*

*

5.2

* 99

*

*

6.1user friendly

*